Lincoln Pharmaceuticals Limited (BSE: 531633, NSE: LINCOLN), one of India’s leading healthcare companies, reported a consolidated net profit of Rs. 87.89 crore for the financial year ended March 31, 2026, compared with Rs. 82.35 crore in FY25, reflecting a 6.74% Y-o-Y increase. Revenue from Operations for FY26 was Rs. 704.48 crore, compared with Rs. 645.71 crore in FY25, representing a 9.10% Y-o-Y increase. EBITDA for FY26 stood at Rs. 131.14 crore, compared with Rs. 123.97 crore in FY25, a 5.78% Y-o-Y increase. EPS for FY26 was Rs. 43.88 per share. Company has recommended a dividend of 18 %, Rs. 1.80 per share on the face value of Rs. 10 per share for the FY 2025-26.
The company reported a profit before tax of Rs. 115.63 crores for the year ended in March 2026 as against profit before tax of Rs. 109.19_crore in FY24-25. Foreign Institutional Investors (FIIs) have steadily increased their stake in the company to 5.20% while Domestic Institutional Investors (DIIs) holding was 1.08% as on 31st March 2026. Greenx Wealth Multihorizons Opportunity Fund holds 1.07% in the company while Rimo Capital Fund Lp holds 1.33% in the company.
